Overview We are a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancers. Our conditionally active biologics (CAB or CABs) capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH d...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134499 | EDGAR | 102K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046217 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036548 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009551 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002303 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001193125-21-092812 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001193125-25-280435 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105220 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064594 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123506 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094164 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059757 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060389 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0000950170-23-036554 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021358 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0000950170-22-022036 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016149 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0000950170-22-007871 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001193125-26-140053 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-134501 | EDGAR | — |
| 2026-03-23 | 0001193125-26-119698 | EDGAR | — |
| 2026-03-02 | 0001539497-26-000812 | EDGAR | — |
| 2026-02-09 | 0001193125-26-041852 | EDGAR | — |
| 2026-02-06 | 0001193125-26-041367 | EDGAR | — |
| 2026-01-30 | 0001193125-26-031942 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010458 | EDGAR | — |
| 2025-12-31 | 0001193125-25-337646 | EDGAR | — |
| 2025-12-30 | 0001193125-25-337078 | EDGAR | — |
100 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001826892 |
| Ticker | BCAB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.bioatla.com |
| Listed | 2020-12-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report